A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
NCT ID: NCT00443391
Last Updated: 2013-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
141 participants
INTERVENTIONAL
2007-02-28
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00554385
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00686933
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00391729
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
NCT00183391
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
NCT01338818
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ABT-089
Open label study, subjects will take up to 80mg daily for 24 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-089
Open label study, subjects will take up to 80mg daily for 24 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* If female, subject must be either postmenopausal for at least 1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing at least a method of birth control throughout the study
* If female, the result of a pregnancy tests are negative
* The subject is judged to be in generally good health
Exclusion Criteria
* The subject has taken any ADHD medication between the last dose of study drug in Study M06-855 and the first dose of study drug in the current study
* The subject anticipates a move outside the geographic area
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie (prior sponsor, Abbott)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laura Gault, MD, PhD, MD
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Reference ID/Investigator# 6109
Mesa, Arizona, United States
Site Reference ID/Investigator# 6765
Mesa, Arizona, United States
Site Reference ID/Investigator# 6100
Lafayette, California, United States
Site Reference ID/Investigator# 6107
San Diego, California, United States
Site Reference ID/Investigator# 6112
Jacksonville, Florida, United States
Site Reference ID/Investigator# 6096
Maitland, Florida, United States
Site Reference ID/Investigator# 6105
Tampa, Florida, United States
Site Reference ID/Investigator# 6094
Smyrna, Georgia, United States
Site Reference ID/Investigator# 6111
Newton, Kansas, United States
Site Reference ID/Investigator# 6113
Farmington Hills, Michigan, United States
Site Reference ID/Investigator# 6110
Omaha, Nebraska, United States
Site Reference ID/Investigator# 6099
New York, New York, United States
Site Reference ID/Investigator# 6106
Chapel Hill, North Carolina, United States
Site Reference ID/Investigator# 6102
Portland, Oregon, United States
Site Reference ID/Investigator# 6097
Charleston, South Carolina, United States
Site Reference ID/Investigator# 6098
Memphis, Tennessee, United States
Site Reference ID/Investigator# 6103
Austin, Texas, United States
Site Reference ID/Investigator# 6104
Lake Jackson, Texas, United States
Site Reference ID/Investigator# 6095
Herndon, Virginia, United States
Site Reference ID/Investigator# 6092
Seattle, Washington, United States
Site Reference ID/Investigator# 6101
Middleton, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M06-889
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.